drugset / Trial / NCT04782180
PrEP at a Syringe Services Program
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2024-11-11
- Completion
- 2024-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tenofovir alafenamide | Small molecule | 25 mg | Oral |
| Subject | tenofovir alafenamide | Small molecule | 200 mg | Oral |